D. Boral Capital Cuts Tevogen Bio (NASDAQ:TVGN) Price Target to $2.00

Tevogen Bio (NASDAQ:TVGN) had its price objective reduced by D. Boral Capital from $5.00 to $2.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $2.00.

Tevogen Bio Stock Performance

Shares of NASDAQ TVGN opened at $0.16 on Tuesday. The stock has a 50 day moving average price of $0.30 and a 200 day moving average price of $0.53. The stock has a market capitalization of $30.82 million, a PE ratio of -0.82 and a beta of -0.76. Tevogen Bio has a 52 week low of $0.14 and a 52 week high of $1.51.

Institutional Trading of Tevogen Bio

Hedge funds have recently made changes to their positions in the business. Bridgeway Capital Management LLC increased its holdings in shares of Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after acquiring an additional 33,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the period. Finally, Deutsche Bank AG increased its holdings in shares of Tevogen Bio by 304.1% in the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.